ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen To Buy Mustafa Nevzat For $700 Million

Biotechnology firm Amgen (AMGN) will buy a 95.6% stake in Mustafa Nevzat Pharmaceuticals for $700 million, in a move to expand its presence in Turkey and the surrounding region. The all-cash transaction has been approved by both the boards, the two companies said in a joint statement Wednesday. MN, which supplies pharmaceuticals to the hospital sector and is a major supplier of injectable medicines in Turkey, had revenue of approximately $200 million in 2011, the statement said. Amgen's focus on Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen, is a part of its international expansion strategy. Amgen established an affiliate in Turkey in 2010 and currently markets two products, with plans to develop its pipeline of clinical candidates for Turkey and other markets around the world. Order free Annual Report for Amgen, Inc. Visit http://djnewswires.ar.wilink.com/?link=AMGN or call 1-888-301-0513

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
09/23/201620:12:00FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23/201619:10:00FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23/201618:56:00FDA Approves Amgen's Biosimilar Version of Humira
09/23/201618:04:00FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment O...
09/20/201609:00:00Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV...
09/18/201611:00:00Results From Phase 3 FRAME Study Of Romosozumab Showed Significant...
09/16/201607:34:00Amgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) F...
09/15/201616:30:00Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab...
09/14/201616:00:00Amgen To Webcast Investor Call
09/13/201618:22:22Statement of Changes in Beneficial Ownership (4)
09/13/201616:00:00Amgen to Present at the Bank of America Merrill Lynch Global...
09/13/201603:02:00Credit Markets: Apple, Daimler on BOE List -- WSJ
09/12/201616:00:00Bank of England Lists Corporate Bonds Eligible for Purchase
09/12/201615:46:00Bank of England Lists Corporate Bonds Eligible for Purchase
09/08/201616:00:00Amgen To Present At The Morgan Stanley Global Healthcare Conference
09/07/201616:00:00Amgen to Highlight 19 Abstracts on Osteoporosis Disease State...
09/02/201608:40:00Merck Discontinues Development of Osteoporosis Drug
09/01/201616:00:00FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients...
09/01/201611:35:00Cytokinetics Heart Drug Moves to Late-Stage Development
09/01/201611:34:00Amgen Acquires Rights to Multiple Myeloma Therapy From Boehringer

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad